Antineoplastics
1
Reactions 1470, p8 - 21 Sep 2013 S Antineoplastics Neutropenia, diarrhoea and neuropathy: 5 case reports Three women and two men aged 62–79 years developed neutropenia (3 patients), neuropathy (4) and diarrhoea (1) while receiving gimeracil/oteracil/tegafur [S-1], oxaliplatin and bevacizumab [durations of treatment to reactions onset and outcomes not stated]. All patients had clinically curative resectable liver metastases of colorectal cancer. They received 3 cycles of preoperative chemotherapy consisting of IV bevacizumab 7.5 mg/kg and IV oxaliplatin 130 mg/m 2 on day 1, with oral gimeracil/oteracil/tegafur 80 mg/m 2 for 14 days followed by a 7-day medication pause, plus a fourth cycle of gimeracil/ oteracil/tegafur + oxaliplatin with bevacizumab omitted. Resection was performed at least 35 days after the last administration of bevacizumab and at least 21 days after the last administration of gimeracil/oteracil/tegafur + oxaliplatin. Adverse events included grade 3 neutropenia (1 patient), grade 3 diarrhoea (1), grade 1 neutropenia (2) and grade 1 neuropathy (4). The patient with diarrhoea discontinued chemotherapy after 2 cycles because of adverse effects. Author comment: As regards side effects, apart from 1 case of confirmed grade 3 neutropenia and 1 case of confirmed grade 3 diarrhoea there was 4 cases of grade 1 numbness and 3 cases of grade 1 neutropenia. Takahashi D, et al. Evaluation of S-1 + Oxaliplatin + Bevacizumab combination chemotherapy as neoadjuvant chemotherapy for patients with resectable liver metastases from colorectal cancer. Japanese Journal of Chemotherapy 61: 343-346, No. 4, Jan 2013 [Japanese; summarised from a translation] - Japan 803093148 1 Reactions 21 Sep 2013 No. 1470 0114-9954/13/1470-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1470, p8 - 21 Sep 2013
SAntineoplastics
Neutropenia, diarrhoea and neuropathy: 5 casereports
Three women and two men aged 62–79 years developedneutropenia (3 patients), neuropathy (4) and diarrhoea (1)while receiving gimeracil/oteracil/tegafur [S-1], oxaliplatin andbevacizumab [durations of treatment to reactions onset andoutcomes not stated].
All patients had clinically curative resectable livermetastases of colorectal cancer. They received 3 cycles ofpreoperative chemotherapy consisting of IV bevacizumab 7.5mg/kg and IV oxaliplatin 130 mg/m2 on day 1, with oralgimeracil/oteracil/tegafur 80 mg/m2 for 14 days followed by a7-day medication pause, plus a fourth cycle of gimeracil/oteracil/tegafur + oxaliplatin with bevacizumab omitted.Resection was performed at least 35 days after the lastadministration of bevacizumab and at least 21 days after thelast administration of gimeracil/oteracil/tegafur + oxaliplatin.Adverse events included grade 3 neutropenia (1 patient),grade 3 diarrhoea (1), grade 1 neutropenia (2) and grade 1neuropathy (4). The patient with diarrhoea discontinuedchemotherapy after 2 cycles because of adverse effects.
Author comment: As regards side effects, apart from1 case of confirmed grade 3 neutropenia and 1 case ofconfirmed grade 3 diarrhoea there was 4 cases of grade 1numbness and 3 cases of grade 1 neutropenia.Takahashi D, et al. Evaluation of S-1 + Oxaliplatin + Bevacizumab combinationchemotherapy as neoadjuvant chemotherapy for patients with resectable livermetastases from colorectal cancer. Japanese Journal of Chemotherapy 61: 343-346,No. 4, Jan 2013 [Japanese; summarised from a translation] - Japan 803093148
1
Reactions 21 Sep 2013 No. 14700114-9954/13/1470-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved
